 |
|
|
| |
Efficacy and Safety of Bemnifosbuvir and Ruzasvir After 8 Weeks of Treatment in Patients With Chronic Hepatitis C Virus (HCV) Infection
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Alina Jucov,1,2 Saeed Hamid,3 Laura Iliescu,4 Elena Ermacicova,1 Shannan Lynch,5
Marina Majarian,5 Sergey Izmailyan,5 Qi Huang,5 Xiao-Jian Zhou,5 Keith Pietropaolo,5 Bruce Belanger,5
Arantxa Horga,5 Janet Hammond5
1. Arensia Exploratory Medicine GmbH, Chisinau, Moldova; 2. Nicolae Testemitanu State University of Medicine and Pharmacy,
2. Chisinau, Moldova;
3. Aga Khan University, Karachi, Pakistan; 4. Institutul Clinic Fundeni, Bucharest, Romania; 5. Atea Pharmaceuticals Inc. Boston, USA
EASL2024: Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier
AASLD 2024: Bemnifosbuvir Poses High Barrier for Resistance in Both Preclinical and Phase 1b Monotherapy Studies
Multiscale modeling of lead-in results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection
AASLD2023: Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination
EASL2023: Lead-in Cohort Results From a Phase 2 Study of a Novel 8-week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients With Chronic Hepatitis C Virus Infection
Lack of pharmacokinetic drug-drug interaction between bemnifosbuvir and ruzasvir in healthy participants
Bemnifosbuvir Does Not Alter Cardiac Repolarization in Healthy Participants: Results from a Thorough QT Study
|
| |
|
|
|
|
|
